In a combined (cross-sectional and longitudinal) study, the serum concentration of laminin P1 was measured by radioimmunoassay in 16 patients with benign inflammatory bladder disorders and 47 patients with transitional cell carcinoma of the bladder. The results were compared with the serum laminin PI values in 50 healthy control subjects. In the cross-sectional study, the mean value of serum laminin PI was significantly higher in bladder cancer patients than either the controls (p < 0.0001) or patients with benign inflammatory bladder disorders (p < 0.001). Similarly, the mean values of all different stages of grades of the tumor were significantly higher than either the controls or patients with benign inflammatory disorders. Progressive increase in the mean values of serum laminin P1 could also be found with deterioration of the stage or grade of the tumor. However, the difference between the mean values of the different cancer stages or grades did not reach statistical significance. In the longitudinal study, no significant difference could be detected between the mean values of patients with superficial tumor recurrence and those with remission of the disease (p > 0.5). Nevertheless, in the invasive cancer group, the levels of serum laminin PI were directly proportional with progression of the disease (Z = 2.94; p < 0.01).

Keywords:
Serum laminin, Bladder cancer
This content is only available via PDF.
© 1992 S. Karger AG, Basel
1992
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.